SDS-Page
N-Acetylgalactosaminidase Alpha (NAGa) Recombinant Protein | NAGa recombinant protein
Recombinant N-Acetylgalactosaminidase Alpha (NAGa)
MGHHHHHHSGSEF- IQD SWKSVLSILD WFVRHQDVLQ PVAGPGHWND PDMLLIGNFG LSFDESRAQM ALWTVLAAPL LMSTDLRTIS PQNMDILQNP LMIKINQDPL GIQGRRILKS KSHIEVFKRY LSNQASALVF FSRRTDMPFR FHCSLLELNY PKGRVYEGQN VFTGDIFSGL QTEVNFTVII NPSGVVMWYL YPIKDLGIST MMSHW
Stability Test: The thermal stability is described by the loss rate of the targetprotein. The loss rate was determined by accelerated thermal degradation test,that is, incubate the protein at 37 degree C for 48h, and no obvious degradation andprecipitation were observed. (Referring from China Biological Products Standard,which was calculated by the Arrhenius equation.) The loss of this protein is lessthan 5% within the expiration date under appropriate storage condition.
SDS-Page
SDS-Page
NCBI and Uniprot Product Information
Uniprot Description
NAGA: Removes terminal alpha-N-acetylgalactosamine residues from glycolipids and glycopeptides. Required for the breakdown of glycolipids. Defects in NAGA are the cause of Schindler disease (SCHIND). Schindler disease is a form of NAGA deficiency characterized by early onset neuroaxonal dystrophy and neurological signs (convulsion during fever, epilepsy, psychomotor retardation and hypotonia). NAGA deficiency is typically classified in three main phenotypes: NAGA deficiency type I (Schindler disease or Schindler disease type I) with severe manifestations; NAGA deficiency type II (Kanzazi disease or Schindler disease type II) which is mild; NAGA deficiency type III (Schindler disease type III) characterized by mild-to-moderate neurologic manifestations. NAGA deficiency results in the increased urinary excretion of glycopeptides and oligosaccharides containing alpha-N-acetylgalactosaminyl moieties. Inheritance is autosomal recessive. Defects in NAGA are the cause of Kanzaki disease (KANZD); also known as NAGA deficiency type II or Schindler disease type II. Kanzaki disease is an autosomal recessive disorder characterized by late onset, angiokeratoma corporis diffusum and mild intellectual impairment. Belongs to the glycosyl hydrolase 27 family.
Protein type: Hydrolase; Glycan Metabolism - glycosphingolipid biosynthesis - globo series; EC 3.2.1.49
Cellular Component: lysosome; cytoplasm
Molecular Function: protein homodimerization activity; hydrolase activity; alpha-galactosidase activity; hydrolase activity, acting on glycosyl bonds; catalytic activity; alpha-N-acetylgalactosaminidase activity; hydrolase activity, hydrolyzing O-glycosyl compounds
Biological Process: glycolipid catabolic process; carbohydrate catabolic process; glycoside catabolic process; metabolic process; carbohydrate metabolic process; glycosylceramide catabolic process; oligosaccharide metabolic process
Research Articles on NAGa
Similar Products
Product Notes
The NAGa naga (Catalog #AAA2009194) is a Recombinant Protein produced from E Coli and is intended for research purposes only. The product is available for immediate purchase. AAA Biotech's N-Acetylgalactosaminidase Alpha (NAGa) can be used in a range of immunoassay formats including, but not limited to, SDS-PAGE, Western Blot (WB), ELISA (EIA), Immunoprecipitation (IP). Researchers should empirically determine the suitability of the NAGa naga for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process. The amino acid sequence is listed below: The target protein is fused with N-terminal His-Tag, its sequence is listed below. MGHHHHHHSG SEF- IQD SWKSVLSILD WFVRHQDVLQ PVAGPGHWND PDMLLIGNFG LSFDESRAQM ALWTVLAAPL LMSTDLRTIS PQNMDILQNP LMIKINQDPL GIQGRRILKS KSHIEVFKRY LSNQASALVF FSRRTDMPFR FHCSLLELNY PKGRVYEGQN VFTGDIFSGL QTEVNFTVII NPSGVVMWYL YPIKDLGIST MMSHW. It is sometimes possible for the material contained within the vial of "N-Acetylgalactosaminidase Alpha (NAGa), Recombinant Protein" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
